Back to search results
NCT06323044

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Recruiting
NAAll AgesInterventionalSupportive care
Roswell Park Cancer Institute
~150 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:Best PracticeBiospecimen CollectionElectronic Health Record ReviewInterviewMedical Device Usage and EvaluationSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Medication adherence
Measured over Up to 1 year

Conditions

Acute Lymphoblastic Leukemia

Explore related trials

Acute Lymphoblastic Leukemia

NCT06323044

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Roswell Park Cancer Institute

    Buffalo, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kara M Kelly · PRINCIPAL_INVESTIGATOR · Roswell Park Cancer Institute

Who to contact

Kara M. Kelly
[email protected]
716-845-2333
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)
Child patient age 365 days to \< 19 years at time of study entry.
Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.
Verbal fluency in English, or Spanish
Parent has a smartphone or computer access with an Internet connection.
Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion

Parent is unwilling or unable to follow protocol requirements.

What this trial measures

  • Medication adherenceUp to 1 year

    Will be summarized by timepoint (baseline, 6-months, and 1-year) and condition using descriptive statistics and graphical summaries. The primary analysis will model log adherence as a function of condition, timepoint, their two-way interaction, and random family (accounting for the longitudinal measures within a family unit) and site (accounting for between cancer center variability) effects using a linear mixed model (LMM). Bonferroni adjusted tests about the appropriate contrasts of model estimates will be used to compare: 1) the mean change in adherence within each condition, 2) retention of effect at 12-months within each condition, and 3) the mean change in adherence between conditions.